Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.

Authors

Mark Harrison

Mount Vernon Hospital, Northwood, United Kingdom

Mark Harrison , Sandy Beare , John A. Bridgewater , Ian Chau , Vicky Goh , Alec Mcdonald , Lucinda Melcher , Brendan J. Moran , Melanie Osborne , Philip Quirke , Harpreet Wasan , Wailup Wong , Robert Glynne-Jones

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

First Author: Johanna C. Bendell

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.

First Author: Hideaki Bando

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).

First Author: Angela Damato

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.

First Author: Wen Zhang